LON:IMM ImmuPharma (IMM) Share Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free IMM Stock Alerts GBX 2.16 -0.02 (-0.92%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range 2.11▼ 2.2050-Day Range 0.85▼ 2.5752-Week Range 0.82▼ 3.80Volume732,551 shsAverage Volume2.48 million shsMarket Capitalization£9.00 millionP/E RatioN/ADividend Yield0.77%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get ImmuPharma alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About ImmuPharma Stock (LON:IMM)ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.Read More IMM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMM Stock News HeadlinesApril 2, 2024 | lse.co.ukImmupharma jumps amid new IP strategy for P140 technology platformMarch 25, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesApril 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? March 15, 2024 | msn.comSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 8, 2024 | finance.yahoo.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsFebruary 24, 2024 | morningstar.comImmuPharma PLC IMMFebruary 21, 2024 | lse.co.ukUK government borrowing surplus rises in January from prior yearJanuary 17, 2024 | ca.finance.yahoo.comImmuPharma PLC (25I.SG)April 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? December 19, 2023 | lse.co.ukEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsAugust 31, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | marketwatch.comImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 21, 2023 | lse.co.ukImmuPharma agrees 12 month extension to Incanthera warrant instrumentJune 27, 2023 | proactiveinvestors.comImmuPharma "absolutely delighted" to push on with new clinical trialJune 19, 2023 | proactiveinvestors.comImmuPharma presses on with next phase of Lupuzor clinical trialsMay 24, 2023 | proactiveinvestors.comImmuPharma "looking forward with quiet confidence" to FDA responseMay 18, 2023 | uk.investing.comFTSE 100 remains higher but off best with Wall Street indicated mixedMay 18, 2023 | marketwatch.comImmuPharma Shares Rise on Positive Guidance From US FDA for P140May 18, 2023 | proactiveinvestors.comImmuPharma shares jump 6.5% after FDA updateMay 18, 2023 | proactiveinvestors.comImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorMay 12, 2023 | marketwatch.comSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029May 11, 2023 | proactiveinvestors.comImmuPharama eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma eyes clinical trial progressApril 27, 2023 | proactiveinvestors.comImmuPharma "looking forward" to upcoming FDA meetingsApril 19, 2023 | proactiveinvestors.comImmuPharma partner gets FDA meeting dateApril 12, 2023 | marketwatch.comImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical ProgramApril 12, 2023 | proactiveinvestors.comImmuPharma rises 4% after it reveals headway with lead assetSee More Headlines Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CUSIPN/A CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-159.35% Return on Assets-53.90% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.03 Sales & Book Value Annual Sales£94,819.00 Price / Sales94.87 Cash FlowGBX 0.11 per share Price / Cash Flow20.50 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares416,440,000Free FloatN/AMarket Cap£9.00 million OptionableNot Optionable Beta1.32 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Timothy Paul McCarthy XIV (Age 68)FCCA, M.B.A., MBA, Chairman & CEO Comp: $106.5kDr. Timothy Gary Franklin M.B.A. (Age 60)Ph.D., COO & Director Comp: $92.5kMs. Lisa Baderoon (Age 58)Head of Investor Relations & Non Executive Director Comp: $48kDr. Jean-Marie Geiger PharmDMD, Head of Clinical DevelopmentDr. Laura Mauran-Ambrosino Ph.D.Chief Scientific Officer of ImmuPharma BiotechMs. Lara E. Sucheston-CampbellHead of Clinical & Medical AffairsDr. Sébastien R. Goudreau Ph.D. (Age 43)CEO of ImmuPharma Biotec & Director More ExecutivesKey CompetitorsBiVictriX TherapeuticsLON:BVXRoquefort TherapeuticsLON:ROQGenflow BiosciencesLON:GENFBSF EnterpriseLON:BSFARealm TherapeuticsLON:RLMView All Competitors IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed in 2024? ImmuPharma's stock was trading at GBX 1.67 on January 1st, 2024. Since then, IMM shares have increased by 29.5% and is now trading at GBX 2.16. View the best growth stocks for 2024 here. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($1.69) earnings per share for the quarter. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Energy (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA). How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:IMM) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
